Metabolic network abnormalities in early Huntington's disease: An [18F]FDG PET study

Journal of Nuclear Medicine

Volumn 42, Issue 11, 2001, Pages 1591-1595

  Feigin, A ^a   Leenders, K L ^a   Moeller, J R ^a   Missimer, J ^a   Kuenig, G ^a   Spetsieris, P ^a   Antonini, A ^a   Eidelberg, D ^a  

^a Department of Medicine   (United States)

Author keywords

Brain metabolism; Huntington's disease; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN METABOLISM; CAUDATE NUCLEUS; CLINICAL ARTICLE; DISEASE COURSE; DISEASE MARKER; GENE EXPRESSION; GLUCOSE BRAIN LEVEL; GLUCOSE UTILIZATION; HUMAN; HUNTINGTON CHOREA; OCCIPITAL CORTEX; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

ADULT; BRAIN; BRAIN CHEMISTRY; BRAIN MAPPING; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HETEROZYGOTE; HUMANS; HUNTINGTON DISEASE; MALE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035209380     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. 18FDG and computed tomographic scan
2. PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline
3. Positron emission tomography in the early diagnosis of Huntington's disease
4. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease
5. Normal caudate glucose metabolism in persons at risk for Huntington's disease
6. 2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
7. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease
8. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease
9. Influence of size of regions of interest on PET evaluation of caudate glucose consumption
10. 2 receptor binding in patients with Huntington's disease and other choreas: A PET study
11. 2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease
12. 11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length
13. Functional brain networks in DYTI dystonia
14. Huntington disease: Clinical care and evaluation
15. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis
16. Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders: A principal component approach to modeling brain function in disease
17. Reproducibility of regional metabolic covariance patterns: Comparison of four populations
18. The metabolic topography of parkinsonism
19. Metabolic correlates of pallidal neuronal activity in Parkinson's disease
20. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET
21. The metabolic topography of normal aging
22. Striatal connections of the parietal association cortices in rhesus monkeys
23. Neuropathological classification of Huntington's disease
24. Behavioral and psychiatric symptoms associated with Huntington's disease
25. Executive and mnemonic functions in early Huntington's disease
26. The cortical lesion of Huntington's disease: Further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex
27. 1H NMR spectroscopy studies of Huntington's disease: Correlations with CAG repeat numbers
28. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons
29. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease
30. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy
31. Correction for partial volume effects in PET: Principle and validation